When Yoshinobu Yamamoto signed with the Los Angeles Dodgers in 2023, the headline was 12 years and $325 million. But buried inside that deal is something baseball had never seen before: an opt-out clause that has nothing to do with money, performance, or a player deciding he wants out. It depends entirely on whether his right elbow needs surgery.
How the Clause Actually Works
The mechanics are specific. If Yamamoto undergoes Tommy John surgery — or misses 134 or more consecutive days due to a right elbow injury between 2024 and 2029 — he can opt out of the contract after the 2031 or 2033 World Series. If neither of those things happens, his opt-out windows shift earlier: after 2029 or 2031.
In plain terms: the ligament decides the timeline. That’s not a figure of speech. It’s literally written into the contract.
Why Agent Joel Wolfe Pushed for This
Agent Joel Wolfe negotiated the deal, and this wasn’t a quirky request — it was calculated. Elite pitchers in the modern game know their elbows carry an expiration date. Tommy John surgery has become almost a rite of passage on the mound. So why not turn that medical risk into a negotiating asset?
If the elbow fails, Yamamoto gains flexibility. If it holds up, the Dodgers get certainty. Both sides are betting on something different, and both sides accepted the terms.
Traditional opt-outs are tied to unpaid salary after a certain year, or no-trade protections triggered by a roster move. Those depend on human decisions or dollar figures. This one depends on biology. On an MRI. On what the team doctor says. That’s what makes it strange. That’s also what makes it smart.
Why It Still Matters
Yamamoto’s contract didn’t just protect one pitcher — it opened a door. Agents across the league saw that medical protections could be structured as escape clauses, and other teams began exploring similar frameworks.
The deal also includes a no-minor-league-assignment clause and opt-out rights if Yamamoto is traded, giving him near-total control over his career path. The money matters, but control is what the best agents are selling now.
For the Dodgers, the trade-off was straightforward: land an elite starter and accept that if his elbow breaks down, they lose leverage. That bet only works if they trust Yamamoto to take care of himself — and if they trust their own medical staff.
Between 2024 and 2029, every MRI of that right elbow carries contractual weight. Every twinge, every inflammation update, every question in the postgame presser will have implications — not financial ones, but calendar ones.
That’s what separates modern baseball contracts from what came before. Negotiation isn’t just about numbers anymore. It’s about shared risk. It’s about turning the unpredictable into language a contract can hold. And as long as pitchers keep signing long-term deals, more of them will start asking why their ligament didn’t get a say in the terms.
The number to remember: Yamamoto can opt out of his $325 million deal in 2031 or 2033 — but only if his right elbow requires surgery between 2024 and 2029. Medicine, not money, controls the clock.
